Novartis: Single-Arm, Open-Label, Ph2 of MBG453 added to Hypomethylating Agent for MDS
Clinical Trial Grant
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 26, 2022
End Date
October 20, 2025
Awarded By
Novartis Pharmaceuticals Corporation
Start Date
April 26, 2022
End Date
October 20, 2025